Posts in category Long Ideas


Ardelyx Inc (ARDX) Hits the Home Run; BTIG Boosts Price Target

Tim Chiang now sees a bigger per share value for ARDX’s tenapanor in the IBS-C market.

Read more

H.C. Wainwright Says Don’t Write Off MannKind Corporation (MNKD) Just Yet; Bullish Bet Sends Shares Racing 25%

Oren Livnat expects MannKind’s inhaled insulin’s new label will be a real game-changer.

Read more

These Analysts Are Getting More Confident on NVIDIA Corporation (NVDA) and Intel Corporation (INTC) – Here’s Why

One analyst likes Nvidia’s stellar fall video game slate; top analyst cheers Intel’s improved Notebook sales.

Read more

Alnylam Pharmaceuticals, Inc. (ALNY) Picks Up a Price Target Boost from Cowen Following Stellar Phase III Top-Line Data in FAP

Analyst praises Alnylam’s patisiran as best-in-class, even more confident in its safety and tolerability profile.

Read more

Analysts Dial Up Price Targets for Apple Inc. (AAPL) and Micron Technology, Inc. (MU); Here’s Why

Apple’s Soaring ASPs Are Enticing Apple Inc. (NASDAQ:AAPL) is about to reap the rewards of …

Read more

Snap Inc (SNAP) Gets a Price Target Boost on Meaningful Upside Potential for Monetization Per Minute

Analyst sees higher ad revenue per daily active user growth ahead for Snap and attractive valuation.

Read more

Mizuho Forecasts 127% Upside for Adamas Pharmaceuticals Inc (ADMS) Following Higher-Than-Anticipated Gocovri Pricing

Analyst nearly doubles price target between Gocovri pricing and better prospects in Multiple Sclerosis arena.

Read more

Canaccord More Bullish Than Ever on Quidel Corporation (QDEL); Here’s Why

Analyst bumps up price target on QDEL on back of “sweetened” deal to acquire Alere’s BNP Assay segment.

Read more

Oncolytics Biotech Inc. (ONC) Stock Is Significantly De-Risked After End-of-Phase II Meeting with FDA, Cheers Canaccord

Analyst lifts price target on Oncolytics with new clarity from the FDA on Reolysin’s path forward to approval.

Read more

Capricor Therapeutics Inc (CAPR) Investors Throw Bullish Parade After H.C. Wainwright Boosts Price Target

Analyst spotlights a compelling path forward for DMD program and looks to key catalysts in fourth quarter.

Read more